Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.

Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.